Biotech: Life Science Ventures and Commercialization Briefings
INFO
YOUTUBE2026-06-18eu-startups
The Startup Turning Swamps Into Fashion Gold - Interview with Julian Ellis Brown, CEO of Ponda
STANCE
00:00
05:00
10:00
15:00
20:00
25:00
6 intervals • swipe left
The Startup Turning Swamps Into Fashion Gold - Interview with Julian Ellis Brown, CEO of Ponda
Ponda is developing BioPuff, a plant-based insulation made from bulrush cultivated on regenerated wetlands, aiming to create materials that restore the environment. The company emphasizes regenerative practices and partn…
FULL
00:00–05:00
Ponda is developing BioPuff, a plant-based insulation made from bulrush cultivated on regenerated wetlands, aiming to create materials that restore the environment. The company emphasizes regenerative practices and partnerships with farmers to build a sustainable supply chain.
- Julian Ellis-Brown, CEO of Ponda, highlights the companys mission to develop materials that restore the environment, beginning with BioPuff, a plant-based insulation made from bulrush cultivated on regenerated wetlands
- Pondas strategy diverges from conventional supply chains by emphasizing regenerative practices that not only reduce environmental impact but also contribute to ecosystem restoration
- The company collaborates with farmers to implement sustainable practices that protect and rejuvenate wetlands, underscoring the significance of partnerships in establishing a regenerative supply chain
- Ponda secured $2 million in seed funding in November 2025 and has initiated a crowdfunding campaign to facilitate its growth from pilot projects to commercial operations
- Wetlands are essential for carbon sequestration and enhancing biodiversity, positioning them as a focal point for Pondas innovative material development
Read full analysis
STANCE
STANCE MAP
Ponda's Approach to Sustainability
- Highlights the importance of wetlands in carbon sequestration and biodiversity
- Emphasizes partnerships with farmers to create a regenerative supply chain
Challenges in Adoption
- Questions the scalability of wetland farming and potential economic barriers for farmers
- Notes market resistance to adopting new materials in the fashion industry
Neutral / Shared
- Acknowledges the growing interest in sustainable materials across the global market
- Recognizes the role of regulatory support in promoting eco-friendly practices
FULL
05:00–10:00
Ponda is developing BioPuff, a plant-based insulation made from bulrush cultivated on regenerated wetlands, aiming to create materials that restore the environment. The company emphasizes regenerative practices and partnerships with farmers to build a sustainable supply chain.
- Wetlands, which cover only 3% of the Earths land area, are the largest terrestrial carbon reservoirs, storing twice as much carbon as all trees combined and supporting over 50% of global species diversity
- Pondas initiative focuses on regenerating drained wetlands by encouraging farmers to re-wet these areas, enabling the cultivation of bulrush for high-value materials like BioPuff, a plant-based insulation
- The company aims to establish a global supply chain for BioPuff, utilizing the widespread availability of wetlands in temperate and tropical regions to combat wetland degradation
- Ponda is dedicated to making BioPuff accessible to the mass market, targeting a competitive price point that rivals existing insulation materials while delivering superior performance and regenerative advantages
METRICS
OTHER
3%%
details
CONTEXT: land area coverage
WHY: Understanding wetland coverage is crucial for assessing their ecological importance
EVIDENCE: wetlands coverage is 3% of our land area
OTHER
over 50%%
details
CONTEXT: species reliance on wetlands
WHY: This statistic underscores the biodiversity value of wetlands
EVIDENCE: over 50% of all species in the world, rely on them in some way to their survival
FULL
10:00–15:00
Ponda is developing BioPuff, a plant-based insulation made from bulrush cultivated on regenerated wetlands, aiming to create materials that restore the environment. The company emphasizes regenerative practices and partnerships with farmers to build a sustainable supply chain.
- Pondas BioPuff signifies a transformative shift in fashion towards advanced materials that prioritize environmental sustainability and full traceability, surpassing traditional recycled options
- Consumer demand and regulatory changes, particularly in the EU with new eco-design legislation, are driving the need for innovative materials like BioPuff
- The company collaborates with farmers and landowners to build a wetland farming supply chain, showcasing the economic benefits of rewetting land for cultivating wetland crops
- Ponda aims to present a financially attractive model for farmers, emphasizing the benefits of wetland farming amid increasing extreme weather challenges such as flooding and drought
- By merging sustainability with economic feasibility, Ponda intends to disrupt the fast fashion sector and broaden access to regenerative materials beyond just premium brands
FULL
15:00–20:00
Ponda is developing BioPuff, a plant-based insulation made from bulrush cultivated on regenerated wetlands, aiming to create materials that restore the environment. The company emphasizes regenerative practices and partnerships with farmers to build a sustainable supply chain.
- Rewetting agricultural land restores wetlands and enhances resilience against extreme weather, benefiting both the environment and farmers livelihoods
- Ponda has created the largest supply chain for bulrush, the crop used to produce BioPuff, which serves as a sustainable insulation material for various applications, including jackets and automotive products
- Integrating wetland farming into existing agricultural practices is straightforward, primarily requiring the reversal of drainage practices rather than new infrastructure investments
- Farmers are increasingly drawn to BioPuff as it addresses flooding issues that threaten their crops, making it an appealing option for those with waterlogged land
- Pondas dual business model connects farmers with the fashion industry, fostering a regenerative supply chain that supports ecological restoration while promoting innovative materials
METRICS
OTHER
around 145 billion square meters of wadding is made each year globallysquare meters
details
CONTEXT: global market for insulation materials
WHY: This vast market presents a substantial opportunity for BioPuff's adoption
EVIDENCE: around 145 billion square meters of wadding is made each year globally.
FULL
20:00–25:00
Ponda is developing BioPuff, a plant-based insulation made from bulrush cultivated on regenerated wetlands, aiming to create materials that restore the environment. The company emphasizes regenerative practices and partnerships with farmers to build a sustainable supply chain.
- Ponda is exploring various market applications for BioPuff, including uses in interiors and consumer products, showcasing its potential beyond the fashion industry
- The company transitioned to crowdfunding after securing two million from institutional investors, aiming to build a community around wetland farming and support new business opportunities
- Ponda is developing technology to encapsulate bulrush seeds, which can be reintegrated into the farming supply chain, enhancing growth and revenue potential
- The crowdfunding initiative invites retail investors to participate in Pondas growth, with an initial target of 1.4 million, potentially increasing to 1.7 million for expansion efforts
- Ponda operates within a growing ecosystem of sustainable materials, with an estimated 87 million in funding for similar sectors anticipated by 2026, emphasizing its unique position in a competitive landscape
METRICS
OTHER
1.7 millionUSD
details
CONTEXT: maximum potential for crowdfunding campaign
WHY: This increase could provide additional resources for expansion efforts
EVIDENCE: probably go as far as 1.6, maybe 1.7
OTHER
87 millionUSD
details
CONTEXT: estimated funding for sustainable materials sector by 2026
WHY: This highlights the growing interest and investment in sustainable materials
EVIDENCE: I found around 87 million that was moving this year in 2026 for kind of sustainable materials
FULL
25:00–30:00
Ponda is developing BioPuff, a plant-based insulation made from bulrush cultivated on regenerated wetlands, aiming to create materials that restore the environment. The company emphasizes regenerative practices and partnerships with farmers to build a sustainable supply chain.
- Ponda sets itself apart in the next-generation materials sector by creating a unique wetland supply chain and innovating plant-based materials like BioPuff insulation
- The company has secured both private and public funding, including involvement in a £210 million Horizon Europe project focused on wetland regeneration
- Over the next five years, Ponda plans to source materials from tens of thousands of hectares of wetlands, aiming to significantly lower CO2 emissions and boost biodiversity
- Julian Ellis-Brown highlights the essential role of partnerships with farmers and landowners in developing a regenerative supply chain, emphasizing collaboration as a core aspect of their business model
INFO
YOUTUBE2026-06-01this week in startups
This Startup Fused Human Brain Cells with Silicon Chips | E2295
STANCE
00:00
05:00
10:00
15:00
20:00
25:00
30:00
35:00
40:00
45:00
50:00
55:00
60:00
65:00
14 intervals • swipe left
This Startup Fused Human Brain Cells with Silicon Chips | E2295
Cortical Labs has developed the CL1, a biological computer that integrates lab-grown human neurons with silicon chips, representing a breakthrough in biological computing. The company has also established the world's fir…
FULL
00:00–05:00
Cortical Labs has developed the CL1, a biological computer that integrates lab-grown human neurons with silicon chips, representing a breakthrough in biological computing. The company has also established the world's first biological data center to enhance its computing capabilities.
- Cortical Labs has created the CL1, a biological computer that combines lab-grown human neurons with silicon chips, marking a significant leap in biological computing technology
- The CL1 demonstrates a remarkable 5,000-fold increase in sample efficiency compared to conventional reinforcement learning systems, raising ethical questions about the potential for developing conscious systems
- Cortical Labs has launched the worlds first biological data center, which accommodates multiple CL1 units, enhancing its biological computing capabilities
- The CL1 is user-friendly, allowing researchers to program it using Python without the need to develop their own hardware or software
- The company has experienced strong demand, quickly selling out its initial stock of CL1 units and establishing partnerships with several prestigious U.S. institutions
METRICS
OTHER
5,000 times more sample efficient
details
CONTEXT: comparison to conventional reinforcement learning systems
WHY: This efficiency could revolutionize the field of machine learning
EVIDENCE: 5,000 times more sample efficient
Read full analysis
STANCE
STANCE MAP
Cortical Labs
- Merges lab-grown human neurons with silicon chips to create Synthetic Biological Intelligence
- Addresses ethical concerns regarding the potential for creating conscious systems
Pyka
- Successfully scales autonomous drone operations in Brazil for agricultural applications
- Develops the Dropship drone for versatile commercial and military uses
Neutral / Shared
- Both companies emphasize the integration of hardware and software for enhanced user experiences
- Regulatory challenges impact the deployment of autonomous technologies in various markets
FULL
05:00–10:00
Cortical Labs has developed the CL1, a biological computer that integrates lab-grown human neurons with silicon chips, marking a significant advancement in biological computing. The system is designed to leverage the efficiency of neurons for reinforcement learning, potentially outperforming traditional computing systems in specific applications.
- The CL1 biological computer can support up to one million neurons, with a practical configuration utilizing around 200,000 neurons for effective learning
- Cortical Labs is pioneering the integration of biological computing with silicon chips, capitalizing on the superior efficiency of neurons compared to traditional GPUs for reinforcement learning tasks
- An analogy comparing the intelligence of a cockroach highlights that even basic biological systems can demonstrate generalized intelligence, a trait that current machines lack
- Future versions of the CL series are expected to outperform conventional computing systems in specific applications, particularly in drug testing and discovery, by merging biological and silicon technologies
METRICS
OTHER
200,000 neuronsunits
details
CONTEXT: effective learning configuration for the CL1
WHY: This number indicates the practical limit for commercial viability while still enabling learning
EVIDENCE: we go down to about 200,000 neurons A because that's a number that you know we can grow pretty easily
FULL
10:00–15:00
Cortical Labs has developed a biological computer that integrates lab-grown human neurons with silicon chips, achieving a significant efficiency increase over traditional GPU systems. The company is also establishing a biological data center in Melbourne to support onsite neuron growth and reduce operational costs.
- Cortical Labs biological computing system, which combines human neurons with silicon chips, achieves a remarkable 5,000-fold increase in efficiency over traditional GPU systems for reinforcement learning tasks
- The company is establishing a biological data center in Melbourne, with plans to expand to Singapore, enabling onsite neuron growth and reducing supply chain issues and operational costs
- Each biological computing unit operates on approximately 30 watts of energy, presenting a sustainable alternative to conventional data centers that require significant cooling
- While neurons can have a long lifespan with proper maintenance, the system necessitates regular replacement of filtration units to avoid clogging, similar to kidney failure in biological systems
- Cortical Labs is focused on decentralizing the data center model by producing neurons onsite, which enhances self-sufficiency and reduces dependence on external suppliers
METRICS
OTHER
5,000-fold increasetimes
details
CONTEXT: efficiency of biological computing over GPU systems
WHY: This efficiency could revolutionize reinforcement learning applications
EVIDENCE: the neurons we had were 5,000 times more several efficient than their GPU base systems
FULL
15:00–20:00
Cortical Labs is developing biological computers that merge lab-grown human neurons with silicon chips, creating Synthetic Biological Intelligence. The company is establishing a biological data center in Melbourne to support neuron cultivation and enhance operational efficiency.
- Cortical Labs is pioneering biological computers by merging lab-grown human neurons with silicon chips, resulting in Synthetic Biological Intelligence (SBI)
- These biological systems demonstrate a remarkable efficiency, being 5,000 times more effective than traditional GPU systems for reinforcement learning tasks
- The company is setting up a biological data center in Melbourne, with future plans for Singapore, which will facilitate onsite neuron cultivation and alleviate supply chain issues
- Neurons in this system can have a long lifespan with proper care, although some components need regular replacement to maintain functionality
- Cortical Labs is actively engaging in bioethics discussions to address the ethical implications of integrating human neurons with technology, aiming to alleviate public and institutional concerns
FULL
20:00–25:00
Cortical Labs is pioneering biological computing by integrating lab-grown human neurons with silicon chips, creating a new form of intelligence. The company is also establishing data centers to enhance accessibility and scalability of this technology.
- Cortical Labs is working to democratize biological computing by implementing a cloud-based model that lowers accessibility barriers for users
- The company aims to create a shared nomenclature within the biological computing community to enhance collaboration and address ethical concerns
- Cortical Labs has consulted with ethical organizations, including discussions with the Vatican, to align their work with moral standards and address issues related to consciousness in biological systems
- Their technology is currently being applied in major medical research centers for drug discovery and disease modeling, showcasing its potential to improve healthcare outcomes
- The cloud-based approach enables scalable use of biological computers, with plans for data centers in Melbourne and Singapore to support various applications
METRICS
OTHER
200,000 neuronsunits
details
CONTEXT: neuron capacity per data center
WHY: This capacity indicates the potential scale of biological computing applications
EVIDENCE: 200,000 neurons of peace
FULL
25:00–30:00
Cortical Labs is pioneering biological computing by integrating lab-grown human neurons with silicon chips to create Synthetic Biological Intelligence. The company is also democratizing access to this technology through cloud services, allowing users without lab facilities to innovate.
- Cortical Labs is democratizing biological computing by offering cloud access to their technology, enabling users without lab facilities to innovate
- A version of the video game Doom has been developed using their technology, showcasing the ability to create complex applications with minimal biological expertise
- The system utilizes reward and punishment mechanisms for learning in games, raising ethical questions about the implications if the systems were conscious
- Currently, only a small portion of the 120 deployed CL1 units are actively in use due to challenges in biological growth, underscoring the complexities of scaling this technology
METRICS
OTHER
120units
details
CONTEXT: total deployed CL1 units
WHY: This indicates the scale of Cortical Labs' operations and their market reach
EVIDENCE: we have 120 that we've deployed
OTHER
20users
details
CONTEXT: active users on the cloud
WHY: This highlights the current limitations in user engagement and potential growth challenges
EVIDENCE: only about 20 or 30 users are on the cloud moment
FULL
30:00–35:00
Cortical Labs is developing a biological computing system that integrates lab-grown human neurons with silicon chips, enhancing efficiency in reinforcement learning. The company is also raising $30 million to further advance their technology and capabilities.
- Cortical Labs is pioneering a biological computing system that combines lab-grown human neurons with silicon chips, enhancing reinforcement learning efficiency over traditional GPUs
- The company is investigating the use of microfluidic devices to allow multiple users to share a single biological computer while controlling neuron communication
- Cortical Labs is in the process of raising $30 million to advance their research and improve the yield and capabilities of their biological computing technology
- Their technology demonstration includes live streaming neural activity from cell cultures, highlighting the potential for real-time biological data monitoring and analysis
FULL
35:00–40:00
Cortical Labs is developing biological computers that integrate lab-grown human neurons with silicon chips to create Synthetic Biological Intelligence. The company is also seeking skilled developers and may host a hackathon at MIT to foster innovation in this emerging field.
- Cortical Labs is at the forefront of biological computing, merging lab-grown human neurons with silicon chips to develop Synthetic Biological Intelligence (SBI)
- Founder Dr. Hon Weng Chong highlights the superior learning capabilities of these biological computers compared to traditional GPUs, especially in reinforcement learning
- The CL1 system allows developers to use Python for creating applications that harness the unique advantages of biological computing
- Cortical Labs is looking for skilled developers and is considering hosting a hackathon at MIT to encourage innovation in this field
- The conversation shifts to Pyka, which specializes in large drones for agricultural use, showcasing their transition from crop-spraying to broader cargo transport applications
FULL
40:00–45:00
Cortical Labs is developing biological computers that integrate lab-grown human neurons with silicon chips to create Synthetic Biological Intelligence. Pyka has successfully scaled its autonomous aircraft operations in Brazil, becoming the only company to do so commercially.
- Pyka has created a large autonomous aircraft for agricultural tasks, including crop spraying, and has successfully scaled its operations in Brazil, becoming the only company to do so commercially
- The development of Pykas aircraft involved significant advancements in both hardware and software, with the initial prototype being just a small part of the overall effort needed to meet customer demands
- Regulatory changes in Brazil have facilitated the deployment of agricultural drones, while the U.S. maintains stricter regulations that limit commercial operations, such as distance restrictions from the launch site
- Reliability is crucial for Pykas drones, as customers in remote areas rely on consistent performance, prompting the company to continually enhance and adapt its technology
METRICS
OTHER
600 poundsunits
details
CONTEXT: weight of the autonomous aircraft developed by Pyka
WHY: The aircraft's weight is significant for its design and operational capabilities
EVIDENCE: 600 pound what would be about a two passenger autonomous aircraft
OTHER
12 to 13 hour shiftshours
details
CONTEXT: operational shifts for customers using Pyka's drones
WHY: Long shifts indicate high demand and reliance on the technology
EVIDENCE: some our customers are doing 12 to 13 hour shifts
FULL
45:00–50:00
Cortical Labs is pioneering biological computing by merging lab-grown human neurons with silicon chips to create Synthetic Biological Intelligence. The company has raised $30 million to develop its technology, including the establishment of the world's first biological data center.
- Cortical Labs is at the forefront of biological computing, merging lab-grown human neurons with silicon chips to create a new intelligence that surpasses traditional GPUs in reinforcement learning
- The company has secured $30 million in funding to advance its technology, which includes establishing the worlds first biological data center
- Pykas autonomous aircraft are effectively utilized in Brazil for agricultural purposes, benefiting from more lenient regulations that allow for extended operational ranges compared to the U.S
- The economic advantages of Pykas drones are evident in their reduced fuel consumption relative to conventional aircraft, with a return on investment for farmers projected at two to three years based on usage intensity
- In the U.S, the deployment of these drones may adopt a spray as a service model, enabling contractors to operate them for various clients, thus making the technology accessible to smaller farms
METRICS
OTHER
roughly 55 gallons of jet fuel per hourgallons
details
CONTEXT: fuel consumption of competing aircraft
WHY: Understanding this comparison highlights the economic advantages of Pyka's drones
EVIDENCE: roughly 55 gallons of jet fuel per hour
FULL
50:00–55:00
Cortical Labs is developing biological computers that integrate lab-grown human neurons with silicon chips to create Synthetic Biological Intelligence. Pyka has successfully scaled its autonomous aircraft operations in Brazil, focusing on agricultural and military applications.
- The Pelican drone is optimized for agricultural spraying, where the high cost of chemicals necessitates precision in application
- Rising input costs for farming chemicals due to supply chain challenges underscore the importance of efficient spraying methods like those provided by Pelican
- Pelicans user-friendly design allows for faster operator training compared to traditional aerial application pilots, making it a favored option among farmers
- The Dropship, a second-generation cargo drone, was developed in just 180 days and is intended for both commercial logistics and military use
- Military feedback has highlighted a need for drones with longer-range capabilities and multi-mission functionality, which the Dropship aims to address with a range of 1,000 miles and a payload capacity of 500 pounds
FULL
55:00–60:00
Cortical Labs is developing biological computers that integrate lab-grown human neurons with silicon chips, creating Synthetic Biological Intelligence. Pyka has scaled its autonomous aircraft operations in Brazil, focusing on both commercial and military applications.
- The Dropship drone utilizes a hybrid design, featuring a diesel engine for extended range and electric motors for quiet takeoff and landing, making it suitable for both commercial and military uses
- Regulatory hurdles have slowed the mass production of autonomous drones like the Pelican, limiting their operational capabilities and delaying progress in domestic autonomous flight technologies
- Cortical Labs biological computing technology merges human neurons with silicon chips, offering a notable learning advantage over conventional GPUs and prompting discussions about the essence of life and intelligence in machines
- Feedback from military users of the Dropship highlights the demand for drones with longer operational ranges, payload air drop capabilities, and compatibility with heavy fuel, indicating a trend towards more advanced unmanned aerial systems
METRICS
OTHER
30 kilowatts peakkW
details
CONTEXT: peak power of the diesel engine in the Dropship drone
WHY: This power output is essential for the drone's performance
EVIDENCE: the diesel engine is about uh it's like just over 30 kilowatts peak
OTHER
25 kilowattskW
details
CONTEXT: power of each electric motor in the Dropship drone
WHY: This contributes to the drone's takeoff and landing capabilities
EVIDENCE: the electric motors in the front are each about 25 kilowatts
FULL
60:00–65:00
Cortical Labs is developing biological computers that integrate lab-grown human neurons with silicon chips to create Synthetic Biological Intelligence. The company has raised $30 million to support its innovative technology and establish the world's first biological data center.
- The company has vertically integrated its production, allowing for in-house design and manufacturing of critical components, which has led to NDA-compliant product versions
- This vertical integration has slowed development but has enhanced control over quality and design, despite facing challenges with their own designs
- Manufacturing costs in the U.S. are about twice as high as sourcing from China, but owning the design helps alleviate some cost concerns
- The company emphasizes that owning both hardware and software is crucial for a seamless user experience, drawing parallels to successful firms like Apple and Tesla
- Despite a challenging capital landscape for some sectors, the company has secured necessary funding, though additional capital would facilitate faster growth
METRICS
OTHER
about 2xx
details
CONTEXT: cost differential for manufacturing in the U.S. versus China
WHY: Understanding cost differentials is essential for strategic sourcing decisions
EVIDENCE: it's about 2x that's is that a high price component compared to the overall cost of the device
FULL
65:00–70:00
Cortical Labs is pioneering biological computers that merge lab-grown human neurons with silicon chips, aiming to create Synthetic Biological Intelligence. Pyka is expanding its autonomous drone operations in Brazil, focusing on agricultural applications.
- Michael Norcia, co-founder and CEO of Pyka, emphasizes the companys strong social media presence, particularly on LinkedIn and Instagram, to highlight their operations in Brazil
- Pykas website serves as a key resource for job seekers and those interested in their drone technology
- The company is focused on innovative applications for its autonomous drones, including crop-spraying in Brazil, showcasing the practical benefits of their technology
INFO
YOUTUBE2026-05-28eu-startups
The Startup Freezing Humans For Tomorrow - Interview with Dr Emil Kendziorra, CEO of Tomorrow.bio
STANCE
00:00
05:00
10:00
15:00
20:00
25:00
30:00
35:00
40:00
9 intervals • swipe left
The Startup Freezing Humans For Tomorrow - Interview with Dr Emil Kendziorra, CEO of Tomorrow.bio
Dr. Emil Kendziorra transitioned from cancer research to establish Tomorrow.bio, a pioneering cryopreservation company in Europe.
FULL
00:00–05:00
Dr. Emil Kendziorra transitioned from cancer research to establish Tomorrow.bio, a pioneering cryopreservation company in Europe.
- Dr. Emil Kendziorra shifted from a career in cancer research to establish Tomorrow.bio, a leading cryopreservation company in Europe that focuses on preserving both humans and pets
- Tomorrow.bio addresses the gap in European cryopreservation services, offering a unique position in the market with a transparent pricing model
- Kendziorras transition to cryomedicine reflects his commitment to making advanced preservation technologies more accessible to the public
- The company has successfully secured €5 million in funding, showcasing strong investor confidence in the potential of cryopreservation and medical biostasis
- The discussion reveals the operational and emotional challenges encountered during the preservation of the first 20 human patients and 10 pets, highlighting the need for clear communication regarding the limitations of current technology
Read full analysis
STANCE
STANCE MAP
Proponents of Cryopreservation
- Advocate for cryopreservation as a viable alternative to traditional burial, offering potential for future revival
- Highlight the growing interest and investment in cryopreservation technology, indicating a shift towards acceptance
Skeptics of Cryopreservation
- Question the ethical implications and long-term viability of cryopreservation without guaranteed revival
Neutral / Shared
- Acknowledge the current limitations of cryopreservation technology and the need for clear communication with clients
- Recognize the potential for future advancements in medical science to impact the field of cryopreservation
FULL
05:00–10:00
Dr. Emil Kendziorra founded Tomorrow.bio to advance cryopreservation and medical biostasis, driven by a lifelong passion for longevity.
- Dr. Emil Kendziorras passion for longevity and innovation drives his mission to help people extend their lives
- His motivation to enter medicine and research is rooted in a personal belief in the value of life, rather than a specific traumatic event
- Kendziorra initially aimed to obtain both an MD and a PhD to bridge the gap between basic and translational science, ultimately leading to the creation of a longevity-focused company
- He considers Tomorrow.bio his lifes work, viewing previous ventures as essential steps toward tackling the complex issue of human mortality
- The establishment of Tomorrow.bio marks a significant transition from traditional medical research to the pioneering field of cryopreservation, which he believes has great potential for future advancements in longevity
FULL
10:00–15:00
Dr. Emil Kendziorra founded Tomorrow.bio to advance cryopreservation and medical biostasis, viewing it as a significant solution for extending human life.
- Dr. Emil Kendziorra views cryopreservation as a complex yet impactful solution for extending human life, stemming from his extensive background in biological research
- His entrepreneurial journey through various startups culminated in the founding of Tomorrow.bio, which he regards as his lifes work due to its potential to advance longevity
- Kendziorra emphasizes the financial viability of cryopreservation, positioning it as both a mission-driven initiative and a promising business opportunity
- He acknowledges the current limitations of cryopreservation technology, particularly the challenges surrounding the gap between preservation and potential revival, and stresses the need for transparent communication with patients
- Tomorrow.bio has successfully cryopreserved over 20 human patients and 10 pets, providing critical operational and emotional insights that shape their practices
FULL
15:00–20:00
Tomorrow.bio is a pioneering cryopreservation company in Europe, focusing on medical biostasis and the potential for future revival of preserved individuals. The company has over 1,000 members enrolled for cryopreservation, each costing approximately €200,000.
- Cryopreservation offers a viable alternative for individuals with terminal illnesses, allowing them to choose preservation over traditional burial or cremation, with the hope of future medical advancements
- Tomorrow.bios business model is based on a growing membership, with over 1,000 individuals enrolled for cryopreservation, each costing approximately €200,000, indicating substantial revenue potential
- The company is structured to provide long-term care for preserved individuals through a nonprofit foundation, which serves as a legal guardian, thereby mitigating financial risks associated with preservation
- Success is measured in three stages: financial viability through membership growth, successful preservation in animals as a precursor to human trials, and the eventual revival of preserved individuals, which may take decades
- Investors in Tomorrow.bio typically have a long-term investment perspective, including family offices and ultra-high-net-worth individuals, reflecting the unique nature of the cryopreservation market
METRICS
REVENUE
200,000 eurosEUR
details
CONTEXT: cost per cryopreservation
WHY: This indicates substantial revenue potential for the company
EVIDENCE: each cryo preservation is 200,000 euros
FULL
20:00–25:00
Tomorrow.bio is a pioneering cryopreservation company in Europe, focusing on medical biostasis and the potential for future revival of preserved individuals. The company has over 1,000 members enrolled for cryopreservation, each costing approximately €200,000.
- Cryopreservation does not currently ensure revival, as it depends on future technological advancements, making it a riskier alternative to traditional burial or cremation
- Dr. Kendziorra notes that while cryopreservation may offer a better chance of revival than cremation, the exact probabilities remain uncertain and hinge on future medical developments
- The high cost of cryopreservation is attributed to limited demand and the need for specialized medical teams, but economies of scale could significantly lower prices as adoption increases
- Tomorrow.bio plans to enhance accessibility by reducing cryopreservation costs to approximately €25,000 as the technology becomes more mainstream
- The introduction of brain-only preservation provides a more affordable option, although whole-body preservation is still recommended for optimal outcomes
FULL
25:00–30:00
Tomorrow.bio is a pioneering cryopreservation company in Europe, focusing on medical biostasis and the potential for future revival of preserved individuals. The company has over 1,000 members enrolled for cryopreservation, each costing approximately €200,000.
- The cost of cryopreservation is expected to decrease significantly as participation increases, benefiting from economies of scale in storage and operations
- Many clients currently finance cryopreservation through life insurance policies, alleviating the burden of upfront costs
- Brain-only cryopreservation is offered as a more affordable alternative to whole-body preservation, while still aiming to maintain the individuals identity and consciousness
- Future technological advancements, such as 3D printing of body parts, could potentially enable revival after long-term cryopreservation, although this is not expected in the near term
- The creation of a European cryopreservation organization was motivated by the need for improved medical response capabilities, which were insufficient in existing American services
FULL
30:00–35:00
Tomorrow.bio is a rapidly growing cryopreservation company in Europe, focusing on medical biostasis and the potential for future revival of preserved individuals. The company has over 1,000 members enrolled for cryopreservation, each costing approximately €200,000.
- Dr. Emil Kendziorra highlights Tomorrow.bios rapid growth, claiming it is 20 times faster than legacy organizations, and emphasizes improvements in cryopreservation quality and accessibility
- He stresses the importance of market education over competition, noting that Tomorrow.bio currently faces no direct competitors in Europe, allowing the company to focus on informing potential clients about cryopreservation benefits
- Kendziorra addresses the shift in perception of cryopreservation from a fringe concept to a legitimate option for terminally ill patients, often considered only after other medical treatments have failed
- He discusses the financial aspects of cryopreservation, indicating that life insurance policies can help manage costs, making the service more accessible for interested individuals
- The conversation includes the potential impact of future technologies, such as 3D printing of organs, which could improve the chances of reviving individuals who have undergone cryopreservation
FULL
35:00–40:00
Tomorrow.bio is a rapidly growing cryopreservation company in Europe, focusing on medical biostasis and the potential for future revival of preserved individuals. The company has over 1,000 members enrolled for cryopreservation, each costing approximately €200,000.
- Dr. Emil Kendziorra stresses the importance of increasing the number of companies in the cryopreservation sector to improve market education and establish credibility for the technology
- He notes the initial focus on human cryopreservation at Tomorrow.bio, which later expanded to include pets, reflecting a rising interest in preserving animals
- Kendziorra shares his personal commitment to cryopreservation, indicating that he would choose this option over traditional burial or cremation if faced with a terminal illness
- The lack of competition in Europe positions Tomorrow.bio as a leader in cryopreservation, emphasizing quality and accessibility in their services
- He discusses potential innovations in related fields, such as organ bio-banking and cell preservation, highlighting a mission-driven approach to broaden the applications of cryopreservation technology
FULL
40:00–45:00
Tomorrow.bio is a rapidly growing cryopreservation company in Europe, focusing on medical biostasis and the potential for future revival of preserved individuals. The company has over 1,000 members enrolled for cryopreservation, each costing approximately €200,000.
- Dr. Emil Kendziorra highlights the importance of effective communication to enhance public awareness and acceptance of cryopreservation, noting that approximately 20% of individuals in Europe and the US show interest in this option
- He believes that reaching a milestone of 100,000 sign-ups would necessitate demonstrating the effectiveness of cryopreservation through research, potentially creating a cycle of increased interest and investment
- Kendziorra suggests that endorsements from celebrities and influential figures could help legitimize cryopreservation, making it more attractive to the public and fostering broader acceptance
- He argues that the decision between cryopreservation and traditional burial or cremation should be straightforward, as cryopreservation offers the potential for future revival, presenting a compelling alternative for those with terminal conditions
Loading more...